Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide in R/R DLBCL
NCT06015880Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mosunetuzumab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) and transformed indolent B-cell lymphoma, sponsored by National Cancer Institute. Primary endpoint: Safety and tolerability of mosunetuzumab+polatuzumab vedotin+lenalidomide for determination of recommended phase 2 dose. Started May 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)transformed indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT06015880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015880.